Sunday, September 22, 2024 at 7:26 p.m.
Benguérir – On this World Chronic Myeloid Leukemia (CML) Day, Moldiag, a spin-off of Biotechnologie médicale, specializing in the production and marketing of medical diagnostic kits, looks back on its year of marketing the BCR-ABL diagnostic kit after its launch in 2023, to report on its progress.
Since the start of marketing the BCR-ABL Diagnostic Kit, Moldiag has aimed to make this test available, through local production and accessible to patients through an innovative distribution model, indicates a press release from the MAScIR foundation under the Mohammed VI Polytechnic University (UM6P).
Chronic Myeloid Leukemia (CML) is a blood cancer characterized by high production of granulocytes (a type of white blood cell) by the bone marrow, the press release states, noting that patients affected by this disease now have an effective treatment (ITK – Tyrosine Kinase Inhibitors) available as long as its dosage is adequate and it is tolerated.
However, diagnostic management of CML is undoubtedly the key to diagnosing the disease, directing treatment and monitoring the patient.
As price is a significant barrier according to patient associations, Moldiag is committed with partner medical analysis laboratories not to exceed a public price of 1,500 including tax per analysis, the press release states.
At this stage, the gains seen for patients are significant. The test is available continuously, without risk of stock shortages, thus ensuring easy access for all patients.
In addition, its affordable price helps expand access to diagnosis.
In addition, patients benefit from more regular follow-up, promoting better monitoring of the disease. The results of the analysis are obtained quickly, thus offering increased responsiveness in medical decision-making. These improvements contribute to an optimized and safer patient experience.
It is in this context that Moldiag, a spin-off of the MAScIR Foundation, under the UM6P, will continue its efforts to extend its network of partner laboratories across all regions of the Kingdom.
Through the production of this test, the price of which is set to drop further, Moldiag contributes to the health security of the Kingdom as well as to the national strategy for the generalization of medical coverage, national strategies for the manufacturing of health products and technologies and continental public health strategies, the press release would like to remind.
Moldiag is a spin-off of the MAScIR Foundation, whose mission is to produce and communicate molecular diagnostic tests for professional use at a controlled cost.
These tests, based in particular on RT PCR technology, are developed by researchers at the MAScIR Foundation.
Moldiag has a production capacity of up to 6 million tests per month and has several public and private references to its credit.
